6 recruiting, 4 active not recruiting, 2 not yet recruiting. 8 Phase 1, 4 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Active not recruiting 4, Recruiting 3, Not yet recruiting 1 |
| Phase 2 | 4 | Not yet recruiting 2, Recruiting 2 |
| Phase 3 | 2 | Recruiting 2 |
Follow Obrixtamig: new trials by email Literature Review of Obrixtamig trials Research Report on Obrixtamig
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers Obrixtamig, ZL-1310, Atezolizumab - Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Boehringer Ingelheim | 60 | 2026-10-28 | 2026-10-27 |
| A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) Obrixtamig, Pumitamig, Carboplatin - Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Boehringer Ingelheim | 55 | 2026-10-01 | 2026-10-13 |
| A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung Obrixtamig - Large Cell Neuroendocrine Carcinoma of the Lung | Phase 2 | Not yet recruiting | Technische Universität Dresden | 75 | 2026-09-01 | 2026-08-26 |
| DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy Obrixtamig, Carboplatin, Etoposide - Extrapulmonary Neuroendocrine Cancer (epNEC) | Phase 3 | Recruiting | Boehringer Ingelheim | 390 | 2026-07-10 | 2026-10-28 |
| DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy obrixtamig, atezolizumab, carboplatin - Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Phase 3 | Recruiting | Boehringer Ingelheim | 670 | 2026-04-13 | 2026-10-28 |
| A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer BI 764532, [89Zr]Zr-BI 764532 - Small Cell Lung Carcinoma (SCLC), Neuroendocrine Neoplasms | Phase 1 | Recruiting | Boehringer Ingelheim | 12 | 2024-08-06 | 2026-10-14 |
| DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy BI 764532, Topotecan, Single agent chemotherapy - Small Cell Lung Carcinoma (SCLC) | Phase 1 | Active not recruiting | Boehringer Ingelheim | 69 | 2024-02-14 | 2026-09-15 |
| DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer BI 764532, Carboplatin, Etoposide - Small Cell Lung Carcinoma (SCLC) | Phase 1 | Active not recruiting | Boehringer Ingelheim | 46 | 2024-02-14 | 2026-10-27 |
| A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 BI 764532 - Glioma | Phase 1 | Recruiting | Boehringer Ingelheim | 20 | 2024-01-30 | 2026-10-27 |
| DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers BI 764532, Carboplatin, Etoposide - Neuroendocrine Neoplasms | Phase 1 | Active not recruiting | Boehringer Ingelheim | 65 | 2024-01-22 | 2026-10-06 |
| DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers BI 764532, dose 1, BI 764532, dose 2, Ventana DLL3 RxDx assay - Small Cell Lung Carcinoma, Neuroendocrine Neoplasms | Phase 2 | Recruiting | Boehringer Ingelheim | 204 | 2023-10-13 | 2026-07-23 |
| A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 Obrixtamig, Ezabenlimab - Small Cell Lung Carcinoma (SCLC), Neuroendocrine Neoplasms | Phase 1 | Active not recruiting | Boehringer Ingelheim | 45 | 2023-06-27 | 2026-10-27 |
Small Cell Lung Carcinoma (8) · Carcinoma, Neuroendocrine (1) · Glioma (1) · Lung Neoplasms (1)
Boehringer Ingelheim (11) · Technische Universität Dresden (1)
Germany (10) · France (9) · United States (9) · Belgium (8) · Japan (8) · Spain (8) · Netherlands (7) · Poland (6) · China (5) · United Kingdom (5) · Australia (4) · Austria (3) · Portugal (3) · South Korea (3) · Sweden (3)
Martin Wermke, Prof. Dr. med. (1)
2023 (4), 2025 (3)